Related Experiment Video

Updated: Jun 1, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Possible targets of therapy for catecholaminergic polymorphic ventricular tachycardia. - Insight from a theoretical

Yi-Hsin Chan1, Lung-Sheng Wu, Yung-Hsin Yeh

  • 1First Division of Cardiovascular Department, Chang Gung Memorial Hospital, Taiwan.

Circulation Journal : Official Journal of the Japanese Circulation Society
|June 8, 2011
PubMed
Abstract

Insights

Targeting the Na⁺/Ca²⁺ exchanger (I(NaCa)) is most effective for managing catecholaminergic polymorphic ventricular tachycardia (CPVT). Dual blockade of specific ion channels also shows synergistic effects in treating this serious arrhythmia.

Area of Science:

  • Cardiovascular Physiology
  • Computational Biology
  • Pharmacology

Background:

  • Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening arrhythmia with limited therapeutic options.
  • Understanding the molecular mechanisms of CPVT is crucial for developing effective management strategies.

Purpose of the Study:

  • To investigate specific molecular targets for novel therapeutic interventions in CPVT.
  • To elucidate the underlying pathologies of CPVT using a computational cell model.

Main Methods:

  • Incorporation of a mutant Ryanodine receptor 2 (RyR2) into the Luo-Rudy (LRd) cell model to simulate CPVT.
  • Simulation of varied blockade percentages (0-90%) on key ion channels: Na⁺/Ca²⁺ exchanger (I(NaCa)), fast Na⁺ channel (I(Na)), RyR2 receptor (I(rel)), Ca²⁺-ATPase (SERCA) (I(up)), and L-type Ca²⁺ channel (I(Ca(L))).

Main Results:

  • β-adrenergic stimulation increased cardiac myocyte Ca²⁺ load, triggering spontaneous SR Ca²⁺ leakage and arrhythmias.
  • Blockade of I(NaCa) (≤10%) was most effective in suppressing triggered arrhythmias.
  • Dual blockade strategies, including I(Ca(L))/I(up), I(Na)/I(rel), and I(Ca(L))/I(rel), demonstrated synergistic effects in CPVT management.

Conclusions:

  • Targeting the Na⁺/Ca²⁺ exchanger (I(NaCa)) is the most efficacious therapeutic strategy for CPVT.
  • Combined blockade of I(Ca(L))/I(up), I(Na)/I(rel), or I(Ca(L))/I(rel) offers synergistic benefits for CPVT treatment.

More Related Videos

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

Location, Dissection, and Analysis of the Murine Stellate Ganglion07:50

Location, Dissection, and Analysis of the Murine Stellate Ganglion

Published on: December 22, 2020

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Increased pulse rate01:17

Increased pulse rate

Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...